Metastatic Prostate Cancer - Pipeline Review, H2 2013


#173779

55pages

Global Markets Direct

$ 2000

In Stock


Global Markets Directs, 'Metastatic Prostate Cancer Pipeline Review, H2 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Prostate Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Prostate Cancer. Metastatic Prostate Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Metastatic Prostate Cancer.
  • A review of the Metastatic Prostate Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Metastatic Prostate Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Metastatic Prostate Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Metastatic Prostate Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Metastatic Prostate Cancer Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Metastatic Prostate Cancer 8
Metastatic Prostate Cancer Therapeutics under Development by Companies 10
Metastatic Prostate Cancer Therapeutics under Investigation by Universities/Institutes 11
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Early Clinical Stage Products 14
Comparative Analysis 14
Pre-Clinical Stage Products 15
Comparative Analysis 15
Metastatic Prostate Cancer Therapeutics - Products under Development by Companies 16
Metastatic Prostate Cancer Therapeutics - Products under Investigation by Universities/Institutes 17
Companies Involved in Metastatic Prostate Cancer Therapeutics Development 18
Sanofi-Aventis 18
Progenics Pharmaceuticals, Inc. 19
Marshall Edwards, Inc. 20
Actinium Pharmaceuticals, Inc. 21
Metastatic Prostate Cancer - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Combination Products 23
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
pracinostat - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
veliparib - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
cabazitaxel - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Engineered Autologous T Cells + [cyclophosphamide] - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Actimab-P - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
MEDI-6469 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
LU-901 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
[I131] MIP-1095 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
FB-704 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Antiandrogen Nano-Gold Particles - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Metastatic Prostate Cancer Therapeutics - Drug Profile Updates 41
Metastatic Prostate Cancer Therapeutics - Discontinued Products 45
Metastatic Prostate Cancer Therapeutics - Dormant Products 46
Metastatic Prostate Cancer - Product Development Milestones 47
Featured News & Press Releases 47
Jun 28, 2013: Dendreon Receives Positive Opinion for PROVENGE in the European Union 47
May 31, 2013: Dendreon Announces Presentation Of Provenge Data At 2013 ASCO Annual Meeting 47
May 29, 2013: Janssen's Zytiga Receives New Indication Approval From Health Canada For Treatment Of Metastatic Prostate Cancer 48
Mar 19, 2013: GTx Announces Presentation Of Phase II Trial Data Of GTx-758 In Advanced Prostate Cancer At 28th Annual European Association Of Urology Congress 50
Dec 07, 2012: Dr. Reddy's Labs Launches Debiopharm's Pamorelin LA In India For Treatment Of Locally Advanced Or Metastatic, Hormone-dependent Prostate Cancer 50
Jun 27, 2012: Astellas Pharma And Medivation Announce European Regulatory Submission For Enzalutamide For Treatment Of Prostate Cancer 51
Jun 02, 2012: Zytiga's Phase III Results Show Significant Improvement In Radiographic Progression-Free Survival And Trend For Increased Overall Survival In Metastatic Prostate Cancer Patients 51
May 16, 2012: J&J's ZYTIGA Now Available For Eligible Patients In Nova Scotia, Newfoundland And Labrador For Prostate Cancer 52
Feb 24, 2012: Active Biotech And Ipsen Report Tasquinimod Phase II Long Term Safety Data At 27th European Association Of Urology Congress 52

Appendix 54
Methodology 54
Coverage 54
Secondary Research 54
Primary Research 54
Expert Panel Validation 54
Contact Us 55
Disclaimer 55

Number of Products Under Development for Metastatic Prostate Cancer, H2 2013 8
Products under Development for Metastatic Prostate Cancer - Comparative Analysis, H2 2013 9
Number of Products under Development by Companies, H2 2013 10
Number of Products under Investigation by Universities/Institutes, H2 2013 11
Comparative Analysis by Late Stage Development, H2 2013 12
Comparative Analysis by Mid Clinical Stage Development, H2 2013 13
Comparative Analysis by Early Clinical Stage Development, H2 2013 14
Comparative Analysis by Pre-Clinical Stage Development, H2 2013 15
Products under Development by Companies, H2 2013 16
Products under Investigation by Universities/Institutes, H2 2013 17
Sanofi-Aventis, H2 2013 18
Progenics Pharmaceuticals, Inc., H2 2013 19
Marshall Edwards, Inc., H2 2013 20
Actinium Pharmaceuticals, Inc., H2 2013 21
Assessment by Monotherapy Products, H2 2013 22
Assessment by Combination Products, H2 2013 23
Assessment by Stage and Route of Administration, H2 2013 25
Assessment by Stage and Molecule Type, H2 2013 27
Metastatic Prostate Cancer Therapeutics - Drug Profile Updates 41
Metastatic Prostate Cancer Therapeutics - Discontinued Products 45
Metastatic Prostate Cancer Therapeutics - Dormant Products 46
Number of Products under Development for Metastatic Prostate Cancer, H2 2013 8
Products under Development for Metastatic Prostate Cancer - Comparative Analysis, H2 2013 9
Products under Development by Companies, H2 2013 10
Products under Investigation by Universities/Institutes, H2 2013 11
Late Stage Products, H2 2013 12
Mid Clinical Stage Products, H2 2013 13
Early Clinical Stage Products, H2 2013 14
Pre-Clinical Stage Products, H2 2013 15
Assessment by Monotherapy Products, H2 2013 22
Assessment by Combination Products, H2 2013 23
Assessment by Route of Administration, H2 2013 24
Assessment by Stage and Route of Administration, H2 2013 25
Assessment by Molecule Type, H2 2013 26
Assessment by Stage and Molecule Type, H2 2013 27